Edward van Vaesel says Europe generates nearly as much science and IP as the US, but lacks the capital markets, risk appetite and trial infrastructure to translate it. He notes European companies often run first trials in the US or Australia because patient access is faster and cheaper.
Edward van Vaesel says Merck/MSD was reorganizing and firing local staff, which made it willing to discuss out-licensing a shelved compound. Asserta secured rights to a preclinical asset that the big pharma had overlooked. That access was the starting point for the company and a very useful one.
Edward van Vaesel describes Asserta's lead compound as a shelved Merck/MSD asset that came with prior pharma safety and pharmacology data. He says that scrutiny and existing data helped at the start, even though the molecule had never been tested in a leukemia model initially.
Edward van Vaesel says the US team he met had worked on ibrutinib at Pharmacyclics and knew the BTK investigator network. Without that experience and access, funding Asserta from the Netherlands would have been far harder. He says the company might not have secured sufficient funding or reached key investigators if it had stayed Dutch-based.
Edward van Vaesel says pharma claims to want early assets but usually gets interested only after Phase 2A de-risking. BGV's original plan was proof-of-concept then partner, yet it now has two Phase 3 companies; the partnering bar has moved meaningfully later overall for biotech startups.
Edward van Vaesel says European biotechs often run first human trials in the US but also Australia, where patient access is faster, costs are lower and tax benefits exist. He ties this to Europe's fragmented 27-country trial bureaucracy. That makes Europe less attractive for early clinical development.
